Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, Other

BI Returns Amylin Analog WW Rights to Zealand

Here is a brief preview of this blast: Late Friday, Zealand announced it regained the WW development rights for its Amylin analog program, which was previously licensed to Boehringer Ingelheim. Of note, BI will continue to develop BI456906 (QW GLP-1/GCG dual agonist in Ph2) that was also licensed from Zealand for the treatment of T2DM and obesity. Below, FENIX provides insights on the potential factors influencing BI’s decision to return the development rights of the Amylin analog program back to Zealand.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.